ZimVie Shareholders Await Final Chapter as Acquisition Nears Completion
Published on 09/30/2025 at 08:54 | Redaktion boerse-global.de
The trading pattern of ZimVie shares has become remarkably predictable in recent weeks, consistently hovering near the $19 acquisition price proposed by ARCHIMED. This stabilization signals the impending conclusion of the dental implant manufacturer’s public market journey, with the private equity firm poised to take the company private.
ARCHIMED’s substantial offer of $19 per share represents a significant 99 percent premium over ZimVie’s 90-day average price of $9.57. This valuation places the total enterprise value at approximately $730 million. The transaction, scheduled for finalization before year-end 2025, remains contingent upon standard regulatory approvals and shareholder consent. Following completion, ZimVie will delist from the NASDAQ exchange and transition to private ownership.
Despite the substantial premium, the acquisition faces scrutiny. Legal firm Halper... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
